Prescription drug prices have fallen 3.9% since President Donald Trump took office and declined in every month of 2026, with the administration crediting its Most Favored Nation pricing strategy and TrumpRx platform for the sharpest annual drop in more than six decades.
By yourNEWS Media Newsroom
Prescription drug prices in the United States are falling at a pace not seen since 1963, according to the Trump administration, marking a sharp reversal after decades in which Americans frequently paid substantially more for medicines than consumers in other developed countries.
The White House credits President Donald Trump’s Most Favored Nation drug-pricing policy and the administration’s TrumpRx platform with helping drive the decline.
According to a White House announcement, the most recent annual decrease in prescription drug prices is the largest in more than 60 years.
Prescription prices have fallen 3.9% since Trump returned to office and have declined during every month of 2026.
The declines are not limited to prescription medicines.
Nonprescription drug prices have fallen 2.4% over the past year, while prices for medical-care commodities are down 2.7%.
Rep. Jimmy Patronis, R-Fla., credited Trump’s negotiating approach and use of the presidency to pressure drug companies toward lower prices.
“Without even twisting an arm, without trying to pass a new bill, he [Trump] brought all these players together with TrumpRX to lower the cost of prescription drugs, and he continues to do that because this guy understands leverage. He understands the bully pulpit,” Patronis told Just The News.
The administration says TrumpRx has already generated approximately $700 million in savings for patients.
Some of the largest reductions have occurred in drugs that had become particularly expensive for consumers.
GLP-1 medications that previously cost more than $1,000 per month now begin at $149, according to the administration.
Other categories, including insulin, inhalers, fertility treatments and cholesterol medications, have reportedly seen price reductions ranging from 50% to 90%.
The Department of Veterans Affairs has also secured more than $10 billion in pharmaceutical savings during the current fiscal year, according to the administration, with hundreds of billions of dollars in additional long-term savings projected.
The White House has characterized the current reductions as the first time a president has actually driven prescription drug prices lower.
Decades of Drug-Price Growth Reversed
The recent declines follow a much longer period in which prescription medicines became increasingly expensive.
Drug prices had been rising for decades before the recent reversal.
Bureau of Labor Statistics data cited in the report show that prescription drug prices in 2024 were approximately 5.5 times higher than they had been in 1985.
Over that period, drug prices increased at roughly three times the pace of overall inflation.
Cardiovascular medications and insulin and other antidiabetic drugs were among the categories experiencing some of the largest increases.
Brand-name medicines repeatedly posted list-price increases that exceeded general inflation, leaving the average annual cost of many treatments several times higher than during the early 2000s.
Across the longer term, prescription medicines increased faster than overall consumer prices, contributing to increased out-of-pocket expenses and higher insurance premiums.
Net pharmaceutical prices moderated in some recent years after manufacturer rebates were taken into account, but the decades-long rise in prices left many Americans paying elevated amounts for essential medicines before the current downturn.
U.S. Patients Historically Paid More Than Consumers Abroad
One of the administration’s central arguments for its new pricing approach is that American patients have historically carried a disproportionate share of global pharmaceutical costs.
Americans have paid substantially more for brand-name prescription medications than patients in other wealthy countries.
RAND analyses using 2022 data comparing the United States with 33 other OECD nations found that U.S. prices for brand-name drugs were often three to four times higher.
Pharmaceutical manufacturers and some economic studies have argued that those higher U.S. prices generate much of the worldwide revenue needed to finance expensive and risky pharmaceutical research and development.
At the same time, price controls in other countries have allowed foreign health systems to pay closer to manufacturing costs.
Critics of that system have described the arrangement as a form of international free-riding, with American consumers financing a disproportionate amount of pharmaceutical innovation while patients overseas receive many of the same medicines at considerably lower prices.
The Trump administration has made that disparity a central target of its Most Favored Nation strategy.
Most Favored Nation Policy Targets International Price Gap
Under Trump’s approach, the administration has sought to tie U.S. prices more closely to the lowest prices paid by comparable developed countries.
The administration has reached voluntary pricing agreements with 17 major pharmaceutical manufacturers, including Eli Lilly, AbbVie and Johnson & Johnson.
Those companies collectively represent approximately 86% of the branded prescription drug market, according to the report.
The agreements are intended to bring U.S. prices into line with the lowest levels paid in comparable countries.
The administration argues that the policy reduces the historical imbalance under which U.S. consumers effectively subsidized lower prices overseas.
By forcing a closer connection between American prices and those negotiated abroad, the policy seeks to distribute the financial burden of pharmaceutical development more evenly across wealthy nations rather than concentrating it primarily on U.S. patients.
The administration says the combination of Most Favored Nation pricing agreements and TrumpRx has already begun translating that policy into lower consumer costs.
The 3.9% decline in prescription prices since Trump took office, combined with reductions in nonprescription medicines and other medical goods, represents the sharpest reversal in decades of drug-price growth.
While the long-term effect of the policies will depend on whether the declines persist and whether pharmaceutical companies maintain the agreements, the administration says the latest figures demonstrate that the United States is beginning to move away from a system in which Americans routinely paid far more for the same medicines sold abroad.
Original article
Comments